Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3217–3240 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Autism, Sleep Disturbances in Children, Sleep
Interventions: Power Down bedtime manipulation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Basal Cell Carcinoma
Interventions: Two photon fluorescence microscopy imaging; Device
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Victor, New York

Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions: Not listed
Lead sponsor: Adela, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more

Conditions: Cerebral Palsy, Hemiplegic Cerebral Palsy
Interventions: Therapy Together, Usual Care; Behavioral
Lead sponsor: Texas Scottish Rite Hospital for Children; Other
Eligibility: 3 Months to 71 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Spinal Cord Injuries, Neuromodulation
Interventions: Transcutaneous Spinal cord Stimulation, Epidural Spinal Stimulation (ESS); Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 22 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor
Interventions: WEF-001; Drug
Lead sponsor: Auricula Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions: Psychoeducational skills training intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 60 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Gulf War Syndrome
Interventions: Montelukast, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 50 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Eccentric Hypertrophy, Muscle Damage
Interventions: Fast Eccentric, Slow Eccentric; Behavioral
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Adverse Drug Reaction (ADR), Polypharmacy Patients
Interventions: Not listed
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bryan, Texas

Conditions: Depression
Interventions: Computational dissociation of the causes of cognitive rigidity in depression; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Post Operative Pain, Anesthesia, Nerve Block, Shoulder Osteoarthritis
Interventions: Interscalene Catheter, Exparel Single Shot Interscalene Block; Procedure
Lead sponsor: Melinda Seering; Other
Eligibility: 18 Years to 90 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Interventions: elranatamab, Isatuximab SC, Isatuximab SC-OBDS; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Ileal Pouch
Interventions: EXE-346, Placebo; Biological · Other
Lead sponsor: Exegi Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more

Conditions: End Stage Kidney Disease
Interventions: Biorepository; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Interventions: Device specific training, Study clinician/educator visit; Device · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Oligometastatic Renal Cell Carcinoma
Interventions: Pembrolizumab, Radiation therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab; Procedure · Drug · Other + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Burns
Interventions: Investigational Drug, MW-III, Silvadene® Cream 1% [Silver Sulfadiazine]; Drug
Lead sponsor: Skingenix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 1 more

Conditions: Opioid Use Disorder, Sleep, Circadian Rhythms, fMRI Research
Interventions: AYO light glasses (experimental), AYO light glasses (comparator); Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Muse MRgFUS System; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Blood Cancer, Leukemia
Interventions: DIVERSE Review Process; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infections (STIs)
Interventions: Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling; Drug · Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 29 Years · Female only
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Search by objective public record fields.

Differences in Rest, Emotion, and Arousal Modulation in Youth

Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Implementation of Therapy Together

Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Early-Stage Partner in Care Living Alone Plus

Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

Comparing Two Eccentric Protocols on Muscle Damage

IPGx PILOT Whole Genome Sequencing Extension Cohort

Cognitive and Affective Processes Online

Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties

ELISA in Relapsed/Refractory MM

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

Duke APOL1 Research Biorepository

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections